insitro: machine learning with designated data
How insitro aims to improve machine learning-based target discovery by creating its own ‘fit-for-purpose’ data
Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a biopharma deal with Gilead. insitro’s core selling proposition is that it generates "fit-for-purpose" data that takes much of the noise out of machine learning-based target discovery.
Most companies using machine learning to discover targets aggregate previously collected data sets to feed into their software. These can be from genomic,